Cormorant Asset Management

Activity from announced rounds

All recorded activity
Rounds participated in
6
Confirmed lead rounds
0
4 roles undisclosed
New companies
6
First participation on record · 0 follow-on
Funding in participating rounds
$1.1B
6 disclosed · full round size, not this investor’s share

By stage

Series C+3
Series B2
Undisclosed1

By primary sector

Biotech6

By country

United States6

Rounds

6 in all activity
Dren Bio

Dren Bio develops antibody therapies for cancer, autoimmune conditions and other serious diseases.

$350MPrivate financing
Participant
Crystalys Therapeutics

Crystalys Therapeutics develops dotinurad, an oral URAT1 inhibitor for treating gout

$130MSeries B
Role not disclosed
Terremoto Biosciences

Develops highly targeted, small molecule medicines for cancer and rare diseases

$108MSeries C
Role not disclosed
Parabilis Medicines

Develops medicines targeting historically undruggable protein targets in cancer

$305MSeries F
Role not disclosed
Latigo Biotherapeutics

Latigo Biotherapeutics develops non-opioid pain medicines that target peripheral pain signaling.

$150MSeries B
Participant